MULTI-CANCER EARLY DETECTION
GUARD AGAINST 50+ TYPES OF CANCER
EARLY DETECTION MAKES A DIFFERENCE
THE STATISTICS
OF CANCER DEATHS
are caused by cancers without recommended screenings
DETECTED
In a clinical study, Galleri approximately doubled the number of cancers detected with recommended screening.
OF PEOPLE
will develop cancer in their lifetime.
SURVIVAL RATE
When cancer is diagnosed early , the overall 5-year cancer-specific survival rate is 4 times higher than when cancer is diagnosed late.
-What is the Galleri test?
Cancer Detection
Comprehensive Cancer Detection
Galleri redefines cancer screening by adding its capabilities to the limited scope of current tests. While only five types of cancer have recommended screenings, incorporating Galleri increases the chances of detecting other cancers early, facilitating earlier intervention.
Innovative Testing Method
With just one blood test, Galleri can detect a cancer signal shared by over 50 different cancers, enhancing early detection possibilities. It analyzes more than 100,000 DNA regions and over a million specific DNA sites, identifying cancer-specific methylation patterns that indicate the presence of cancer.
Accurate Prediction and Guidance
If Galleri detects a cancer signal, it accurately predicts the tissue type or organ likely affected with 88% accuracy, aiding in the precise direction for further diagnostic procedures. This level of precision supports effective follow-up actions, including lab work or imaging, to confirm the presence of cancer.
Wide Ranging Early Detection
What Cancers Does Galleri® Screen For?
GASTROINTESTINAL CANCERS
Ampulla of Vater
Appendix, Carcinoma
Bile Ducts, Distal
Bile Ducts, Intrahepatic
Bile Ducts, Perihilar
Colon and Rectum
Esophagus and Esophagogastric Junction
Gallbladder
Liver
Neuroendocrine Tumors of the Appendix
Neuroendocrine Tumors of the Colon and Rectum
Pancreas, exocrine
Small Intestine
Stomach
HEAD, NECK, & THORACIC CANCERS
Larynx
Lung
Nasal Cavity and Paranasal Sinuses
Nasopharynx
Oral Cavity
Oropharynx (HPV-Mediated, p16+)
Oropharynx (p16-) and Hypopharynx
Soft Tissue Sarcoma of the Head and Neck
SKIN & SOFT TISSUE CANCERS
Bone
Melanoma of the Skin
Merkel Cell Carcinoma
Mesothelioma, Malignant Pleural
Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs
Soft Tissue Sarcoma of the Retroperitoneum
Soft Tissue Sarcoma of the Trunk and Extremities
Soft Tissue Sarcoma Unusual Histologies and Sites
HEMATOLOGICAL & LYMPHATIC CANCERS
Leukemia
Lymphoma (Hodgkin and Non-Hodgkin)
Plasma Cell Myeloma and Plasma Cell
Disorders
GYNECOLOGICAL & RELATED CANCERS
Breast
Cervix
Uterus, Carcinoma and Carcinosarcoma
Uterus, Sarcoma
Vagina
Vulva
Gestational Trophoblastic Neoplasms
UROGENITAL & RENAL CANCERS
Adrenal Cortical Carcinoma
Bladder, Urinary
Kidney
Ovary, Fallopian Tube and Primary Peritoneum
Penis
Prostate
Testis
Ureter, Renal Pelvis
Increased Risk With Increased Age
Who is Galleri® for?
The Galleri test is primarily designed for adults who are at an elevated risk of developing cancer. Age is the most significant risk factor for cancer, with individuals over 50 being substantially more susceptible. As age increases, so does the risk of cancer, independent of genetic factors, with only a small percentage of cancers being hereditary. This makes the Galleri test particularly suitable for older adults seeking early detection.
- For adults aged 50 or older, due to increased cancer risk with age.
- For those seeking early detection for multiple types of cancers.
- Individuals seeking additional cancer screening due to genetic factors.
- Not for Individuals under the age of 21.
- Not for Individuals who are pregnant.
- Not for Individuals undergoing active cancer treatment.
Understanding the Galleri test
Your Questions Answered
The Galleri cancer test is a blood test developed by Grail Inc. designed to detect multiple types of cancer at early stages when treatment may be more effective. The test works by analyzing cell-free DNA (cfDNA) in the bloodstream for molecular signals associated with cancer. Cancer cells release small fragments of DNA into the bloodstream, known as circulating tumor DNA (ctDNA), which can be detected and analyzed by the Galleri test to identify the presence of cancer.
The Galleri test is designed to detect a wide range of cancer types, including but not limited to lung, breast, colorectal, ovarian, pancreatic, liver, esophageal, stomach, head and neck, and lymphoid cancers. The test is intended for individuals without a known cancer diagnosis and aims to identify multiple cancer types at early stages when treatment may be more effective.
Clinical studies evaluating the performance of the Galleri test have demonstrated promising results in detecting multiple types of cancer at early stages. According to data from clinical trials, the Galleri test has shown high sensitivity for detecting cancer, with a low false-positive rate. However, like any diagnostic test, the accuracy of the Galleri test may vary depending on factors such as the type and stage of cancer, as well as individual patient characteristics.
The Galleri cancer test may be considered for individuals who meet certain criteria, including those who:
- Are aged 50 years or older
- Do not have a known cancer diagnosis
- Are at average risk for developing cancer
- Have not undergone cancer screening within recommended intervals
- Have concerns about their risk of developing cancer or wish to proactively monitor their health
It’s important to note that the Galleri test is not a substitute for routine cancer screening tests recommended by healthcare providers and should be used in conjunction with existing screening guidelines.
Get Started
We want to help you on your journey to achieving your goals.
You can contact us online or call us at (318) 746-3880 to schedule your consultation in Bossier City.
